Hjem › Non-Hodgkins lymfom › North Carolina › Durham
Kliniske studier for Non-Hodgkins lymfom i Durham, NC
16 studier for Non-Hodgkins lymfom søker deltakere på steder i og rundt Durham (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RekruttererFase 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi unna
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RekruttererFase 1/2
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill · 10 mi unna
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
RekruttererObservasjonsstudie
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RekruttererFase 3
- Duke Cancer Institute, Durham
DALY II USA/ MB-CART2019.1 for DLBCL
RekruttererFase 2
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RekruttererObservasjonsstudie
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi unna
Registry of Older Patients With Cancer
RekruttererObservasjonsstudie
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi unna
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RekruttererFase 1
- University of North Carolina, Chapel Hill · 10 mi unna
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
RekruttererFase 1/2
- Duke University Medical Center, Duke Cancer Center, Durham
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
RekruttererFase 4
- Duke University Medical Center, Durham
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
RekruttererFase 4
- Duke University Medical Center, Durham
Study of SGR-1505 in Mature B-Cell Neoplasms
RekruttererFase 1
- Duke University, Durham
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
RekruttererFase 1
- Duke University, Durham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi unna
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RekruttererObservasjonsstudie
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi unna
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
RekruttererFase 1
- University of North Carolina, Chapel Hill · 10 mi unna
Non-Hodgkins lymfom-studier i andre byer
- New York City, NY31 studier
- Houston, TX31 studier
- Boston, MA26 studier
- Nashville, TN21 studier
- Philadelphia, PA20 studier
- Baldwin Park, CA19 studier
- Washington, DC18 studier
- Chicago, IL18 studier
- Atlanta, GA18 studier
- Milwaukee, WI18 studier
- Columbus, OH18 studier
- Dallas, TX17 studier
Andre studier i Durham
- Brystkreft64 studier
- Kreft (alle typer)58 studier
- Ikke-småcellet lungekreft39 studier
- Multipelt myelom37 studier
- Akut myelogen leukemi33 studier
- Metastatisk kreft33 studier
- Prostatakreft32 studier
- Lungekreft32 studier
- Kolorektal kreft28 studier
- Eggstokkreft27 studier
- Kronisk lymfatisk leukemi27 studier
- Hjertesvikt26 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.